Scandion Oncology’s drug SOM-001 demonstrates antibiotic activity in a mouse model infected with MRSA bacteria
Scandion Oncology has received positive results on the antibiotic in vivo effects of SOM-001 and has decided to proceed with preclinical testing.Antibiotic bacterial resistance is a serious medical problem with a high morbidity and mortality of the infected patients. Previously, Scandion Oncology announced that one of its compounds, SOM-001 and a number of analogues have strong anti-bacterial effects also in otherwise antibiotic resistant bacteria. Moreover, SOM-001 kills bacteria via a novel mechanism of action and further, resistance to SOM-001 has not been observed during in vitro